Skip to main content
. 2019 Jul 10;10:641. doi: 10.3389/fgene.2019.00641

Table 1.

Relative expression levels for DNA methylation and transcriptional repression genes between control participants and schizophrenia patients.

Gene CON SCZ p-value1 FDR1 FES CHR p-value2 FDR2 p-value3 p-value4 p-value5
B2M # 1.053 ± 0.364 1.115 ± 0.471 0.675 0.104 0.852 ± 0.396 1.411 ± 0.373 0.015 0.002 0.212 0.034 0.009
CH4 1.045 ± 0.316 1.457 ± 0.438 0.011 0.004 1.326 ± 0.368 1.604 ± 0.487 0.006 0.001 0.056 0.003 0.200
DNMT1 1.044 ± 0.314 1.421 ± 0.456 0.027 0.008 1.336 ± 0.429 1.517 ± 0.494 0.024 0.003 0.063 0.009 0.430
DNMT3A # 1.061 ± 0.380 1.392 ± 0.357 0.015 0.005 1.208 ± 0.210 1.599 ± 0.384 0.004 0.001 0.299 0.004 0.018
DNMT3B 1.064 ± 0.383 1.907 ± 0.870 0.001 0.001 1.621 ± 0.626 2.229 ± 1.029 0.001 0.001 0.011 0.001 0.156
HDAC1 # 1.046 ± 0.338 1.239 ± 0.374 0.131 0.025 1.063 ± 0.205 1.436 ± 0.433 0.029 0.004 0.899 0.024 0.035
HDAC2 1.087 ± 0.452 1.339 ± 0.463 0.109 0.023 1.346 ± 0.471 1.331 ± 0.486 0.217 0.019 n.d. n.d. n.d.
HDAC3 1.037 ± 0.306 1.341 ± 0.359 0.016 0.005 1.173 ± 0.219 1.531 ± 0.402 0.034 0.004 0.084 0.026 0.264
HDAC4 1.067 ± 0.490 1.154 ± 0.301 0.124 0.025 1.037 ± 0.303 1.284 ± 0.256 0.312 0.026 n.d. n.d. n.d.
HDAC5 # 1.045 ± 0.329 1.482 ± 0.369 0.012 0.004 1.370 ± 0.413 1.626 ± 0.265 0.004 0.001 0.165 0.006 0.035
HDAC6 1.053 ± 0.354 1.601 ± 0.557 0.109 0.023 1.401 ± 0.369 1.825 ± 0.666 0.379 0.030 n.d. n.d. n.d.
HDAC7 1.049 ± 0.330 1.427 ± 0.395 0.001 0.001 1.211 ± 0.324 1.669 ± 0.330 0.002 0.001 0.041 0.002 0.211
HDAC8 1.056 ± 0.371 1.309 ± 0.362 0.002 0.001 1.162 ± 0.221 1.498 ± 0.434 0.002 0.001 0.029 0.001 0.120
HDAC9 # 1.049 ± 0.339 1.451 ± 0.441 0.006 0.003 1.274 ± 0.503 1.650 ± 0.263 <0.001 <0.001 0.250 <0.001 0.011
HDAC10 1.101 ± 0.590 1.274 ± 0.406 0.060 0.015 1.106 ± 0.331 1.463 ± 0.418 0.033 0.004 0.441 0.021 0.174
HDAC11 0.949 ± 0.354 1.286 ± 0.418 0.006 0.003 1.176 ± 0.335 1.409 ± 0.488 0.004 0.001 0.193 <0.001 0.078
HMBS 1.078 ± 0.459 1.346 ± 0.397 0.059 0.015 1.185 ± 0.427 1.526 ± 0.287 0.059 0.006 n.d. n.d. n.d.
MBD2 1.041 ± 0.316 1.199 ± 0.381 0.207 0.038 1.029 ± 0.334 1.390 ± 0.353 0.044 0.005 0.928 0.023 0.047
MBD3 # 1.041 ± 0.314 1.618 ± 0.598 0.002 0.001 1.280 ± 0.300 1.998 ± 0.634 <0.001 <0.001 0.077 <0.001 0.008
MECP2 1.070 ± 0.438 1.233 ± 0.472 0.305 0.051 1.037 ± 0.387 1.452 ± 0.482 0.099 0.009 n.d. n.d. n.d.
RBBP4 1.052 ± 0.388 1.162 ± 0.299 0.109 0.023 1.086 ± 0.265 1.246 ± 0.329 0.430 0.033 n.d. n.d. n.d.
RBBP7 1.051 ± 0.356 1.717 ± 0.547 <0.001 <0.001 1.500 ± 0.438 1.962 ± 0.579 <0.001 <0.001 0.010 <0.001 0.082
RPLP0 # 1.064 ± 0.412 1.198 ± 0.635 0.480 0.077 0.857 ± 0.531 1.582 ± 0.531 0.011 0.002 0.288 0.015 0.013
SAP18 1.047 ± 0.347 1.192 ± 0.379 0.242 0.042 1.056 ± 0.277 1.346 ± 0.436 0.137 0.012 n.d. n.d. n.d.
SAP30 0.931 ± 0.404 1.507 ± 0.685 0.012 0.004 1.644 ± 0.789 1.371 ± 0.591 0.030 0.004 0.034 0.126 0.535
SIN3A 1.057 ± 0.373 1.570 ± 0.404 0.001 0.001 1.482 ± 0.381 1.669 ± 0.430 0.002 0.001 0.012 0.002 0.357
TRDMT1 1.080 ± 0.428 1.127 ± 0.357 0.807 0.120 1.052 ± 0.330 1.225 ± 0.393 0.651 0.048 n.d. n.d. n.d.

Bold typeset indicates significant differences [false discovery rate (FDR) < 0.01 or p < 0.05]. Data are presented as mean ± standard deviation.

CON, control participants; SCZ, schizophrenia patients; FES, first episode schizophrenia patients; CHR, chronic schizophrenia patients; n.d., not determined.

1CON vs. SCZ, 2CON vs. FES vs. CHR, 3CON vs. FES, 4CON vs. CHR, 5FES vs. CHR. #Genes included for association analyses with treatment response.